Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L19IL2 and/or L19TNF in locally advanced basal cell carcinoma
NL-OMON61652Phase 2Not yet recruiting
- Sponsor
- Philogen
- Start
- Feb 2026
- Modality
- Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of darleukin and onfekafusp alfa in basal cell carcinoma (BCC) (3 arms), sponsored by Philogen. Primary endpoint: Primary efficacy objective. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
darleukinonfekafusp alfa
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NL-OMON61652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61652.